---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004098"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:21:14.914564+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML

## Summary
- Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.
- Ziftomenib Phase 1: 30% CR rate among 20 NPM1-mutant AML patients at 600 mg recommended Phase 2 dose.
- Registration-directed trial KOMET-001 dosed multiple patients; 85-patient enrollment target in US and Europe.
- FDA cleared IND for KO-2806, next-generation farnesyl transferase inhibitor; Phase 1 trial expected Q3 2023.
- Bristol Myers Squibb made $25M strategic equity investment at $18.25/share; appointed member to steering committee.

## SEC filing metadata
- accession: 0000950170-23-004098
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/0000950170-23-004098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/kura-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004098
- JSON: https://secwatch.observer/filing/0000950170-23-004098.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004098.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/0000950170-23-004098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.